Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: citatuzumab bogatox, mt-3724, ataluren +2 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 325 | 0.85 |
| pathways Reactome | 16 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 10495
Sealed predictions
- RPL22 in dopamine neurons, braak+0.28 (p 0.472) → +0.15 (p 0.699)receipt 10502
Swarm cases
receipt 10502: RPL22 in dopamine neurons, braak
- power
- full sample +0.15 (p 0.561, n 18), 95% CI -0.34 to +0.57. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.12 (p 0.646, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.17 (p 0.498, n 18). could be the mix.
- skeptic
- leave-one-out range +0.05 to +0.29, sign flips 0; without severely affected donors +0.15 (p 0.561, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RPL22 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts